Rosiglitazone, a peroxisome proliferator-activated receptor-gamma, inhibits the Jun NH(2)-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Diabetes

• Publication date

  2002-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2337/DIABETES.51.5.1507PMID 11978649
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Endogenous PPAR gamma mediates anti-inflammatory activity in murine ischemia-reperfusion injury.

  2001cited by this paper
• Endogenous PPARγ mediates anti-inflammatory activity in murine ischemia-reperfusion injury

  2001cited by this paper
• In Vivo Myocardial Protection From Ischemia/Reperfusion Injury by the Peroxisome Proliferator–Activated Receptor-&ggr; Agonist Rosiglitazone

  2001cited by this paper
• Anti-inflammatory actions of 15-deoxy-delta 12,14-prostaglandin J2 and troglitazone: evidence for heat shock-dependent and -independent inhibition of cytokine-induced inducible nitric oxide synthase expression.

  2000cited by this paper
• Roles of PPARs in health and disease

  2000cited by this paper
• Troglitazone improves recovery of left ventricular function after regional ischemia in pigs.

  2000cited by this paper
• Peroxisome proliferator-activated receptor activators inhibit lipopolysaccharide-induced tumor necrosis factor-alpha expression in neonatal rat cardiac myocytes.

  2000cited by this paper
• Peroxisome Proliferator–Activated Receptor Activators Inhibit Lipopolysaccharide-Induced Tumor Necrosis Factor-α Expression in Neonatal Rat Cardiac Myocytes

  2000cited by this paper
• PPARgamma activators down-regulate the expression of PPARgamma in 3T3-L1 adipocytes.

  1999cited by this paper
• Peroxisome proliferator-activated receptors: nuclear control of metabolism.

  1999cited by this paper
• PPARγ activators down‐regulate the expression of PPARγ in 3T3‐L1 adipocytes

  1999cited by this paper
• Troglitazone inhibits angiotensin II‐induced extracellular signal‐regulated kinase 1/2 nuclear translocation and activation in vascular smooth muscle cells

  1999cited by this paper
• Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway.

  1999cited by this paper
• Differential effects of insulin-sensitizers troglitazone and rosiglitazone on ion currents in rat vascular myocytes.

  1999cited by this paper
• PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines.

  1998cited by this paper
• The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation.

  1998cited by this paper
• The new antidiabetic drug MCC-555 acutely sensitizes insulin signaling in isolated cardiomyocytes.

  1998cited by this paper
• The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation

  1998cited by this paper
• PPAR-γ agonists inhibit production of monocyte inflammatory cytokines

  1998cited by this paper
• Activation of mitogen-activated protein kinases and activator protein-1 in myocardial infarction in rats.

  1998cited by this paper
• Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma.

  1998cited by this paper
• Identification of High-Affinity Binding Sites for the Insulin Sensitizer Rosiglitazone (BRL-49653) in Rodent and Human Adipocytes Using a Radioiodinated Ligand for Peroxisomal Proliferator-Activated Receptor γ

  1998cited by this paper
• Identification, Characterization, and Tissue Distribution of Human Peroxisome Proliferator-activated Receptor (PPAR) Isoforms PPARγ2 versus PPARγ1 and Activation with Retinoid X Receptor Agonists and Antagonists*

  1997cited by this paper
• Tissue-specific Pattern of Stress Kinase Activation in Ischemic/Reperfused Heart and Kidney*

  1997cited by this paper
• Nuclear hormone receptor antagonism with AP-1 by inhibition of the JNK pathway.

  1997cited by this paper
• Protective effect of the sodium/hydrogen exchange inhibitors during global low-flow ischemia.

  1996cited by this paper
• Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat.

  1996cited by this paper
• Stimulation of the stress-activated mitogen-activated protein kinase subfamilies in perfused heart. p38/RK mitogen-activated protein kinases and c-Jun N-terminal kinases are activated by ischemia/reperfusion.

  1996cited by this paper
• Cardioprotective effects of troglitazone in streptozotocin-induced diabetic rats.

  1996cited by this paper
• Stimulation of c-Jun kinase and mitogen-activated protein kinase by ischemia and reperfusion in the perfused rat heart.

  1996cited by this paper
• Repeat Treatment of Obese Mice With BRL 49653, a New Potent Insulin Sensitizer, Enhances Insulin Action in White Adipocytes: Association With Increased Insulin Binding and Cell-Surface GLUT4 as Measured by Photoaffinity Labeling

  1995cited by this paper
• An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ) (*)

  1995cited by this paper
• An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma).

  1995cited by this paper
• A New Antidiabetic Agent, BRL 49653, Reduces Lipid Availability and Improves Insulin Action and Glucoregulation in the Rat

  1994cited by this paper
• c-Jun N-terminal phosphorylation correlates with activation of the JNK subgroup but not the ERK subgroup of mitogen-activated protein kinases

  1994cited by this paper
• The stress-activated protein kinase subfamily of c-Jun kinases

  1994cited by this paper
• Intracellular pH and role of Na+/H+ exchange during ischaemia and reperfusion of normal and diabetic rat hearts.

  1990cited by this paper
• Effect of pressure development on oxygen consumption by isolated rat heart.

  1967cited by this paper
• Effects of an intravenous infusion of a potassium-glucose-insulin solution on the electrocardiographic signs of myocardial infarction. A preliminary clinical report.

  1962cited by this paper

• Electroacupuncture posttreatment attenuates the inflammatory injury in rats after MIRI through PPARγ/NF-κb pathway

  2025cites this paper
• Inflammation in cardiovascular-kidney-metabolic syndrome: key roles and underlying mechanisms–a comprehensive review

  2025cites this paper
• Therapeutic Targeting of PPARγ in Nonalcoholic Fatty Liver Disease: Efficacy, Safety, and Drug Development

  2025cites this paper
• The ameliorative effects and mechanisms of abscisic acid on learning and memory.

  2022cites this paper
• Rosiglitazone Ameliorates Cardiac and Skeletal Muscle Dysfunction by Correction of Energetics in Huntington’s Disease

  2022cites this paper
• PPAR-γ Partial Agonists in Disease-Fate Decision with Special Reference to Cancer

  2022cites this paper
• Citri Reticulatae Pericarpium alleviates postmyocardial infarction heart failure by upregulating PPARγ expression

  2021cites this paper
• Traditional Chinese Medication Qiliqiangxin Attenuates Diabetic Cardiomyopathy via Activating PPARγ

  2021cites this paper
• Exploration of combined effect of peroxisome proliferator activated receptor (PPAR) agonist and retinoic acid receptor (RAR) agonist on experimental models of inflammation in rats

  2020cites this paper
• Protective Effects of Polyphenols against Ischemia/Reperfusion Injury

  2020cites this paper
• β-Sitosterol Protects against Myocardial Ischemia/Reperfusion Injury via Targeting PPARγ/NF-κB Signalling

  2020cites this paper
• PPARγ-Independent Side Effects of Thiazolidinediones on Mitochondrial Redox State in Rat Isolated Hearts

  2020cites this paper
• Lifestyle and Food Habits Impact on Chronic Diseases: Roles of PPARs

  2019cites this paper
• Self-regulation of the inflammatory response by peroxisome proliferator-activated receptors

  2019cites this paper
• c-Jun N-Terminal Kinases (JNKs) in Myocardial and Cerebral Ischemia/Reperfusion Injury

  2018cites this paper
• Thiazolidinediones Cause Cardiotoxicity via PPARγ- Independent Mechanism

  2018cites this paper
• Chrysin attenuates interstitial fibrosis and improves cardiac function in a rat model of acute myocardial infarction

  2018cites this paper
• The Role of Peroxisome Proliferator-Activated Receptor γ in Mediating Cardioprotection Against Ischemia/Reperfusion Injury

  2018cites this paper
• Are targeted therapies for diabetic cardiomyopathy on the horizon?

  2017cites this paper
• Peroxisome proliferator-activated receptor γ (PPARγ): A master gatekeeper in CNS injury and repair

  2017cites this paper
• PPAR γ and Its Role in Cardiovascular Diseases Mini

  2017cites this paper
• INVESTIGATION OF EXPERIMENTAL WARM AND COLD KIDNEY ISCHEMIA-REPERFUSION INJURY IN ANIMAL MODEL

  2017cites this paper
• PPARγ and Its Role in Cardiovascular Diseases

  2017cites this paper
• MicroRNA-26a/b and their host genes synergistically regulate triacylglycerol synthesis by targeting the INSIG1 gene

  2016cites this paper
• Protective Effect of PPARγ Agonists on Cerebellar Tissues Oxidative Damage in Hypothyroid Rats

  2016cites this paper
• Aleglitazar, a Balanced Dual PPARα and -γ Agonist, Protects the Heart Against Ischemia-Reperfusion Injury

  2016cites this paper
• Role of Pleiotropic Properties of Peroxisome Proliferator-Activated Receptors in the Heart: Focus on the Nonmetabolic Effects in Cardiac Protection.

  2016cites this paper
• Does Thiazolidinedione therapy exacerbate fluid retention in congestive heart failure?

  2016cites this paper
• Protective effect of pioglitazone on cardiomyocyte apoptosis in low-dose streptozotocin & high-fat diet-induced type-2 diabetes in rats

  2015cites this paper
• Effects of rosiglitazone (PPAR γ agonist) on the myocardium in non‐hypertensive diabetic rats 罗格列酮（PPAR γ 激动剂）对非高血压糖尿病大鼠的心肌的影响

  2015cites this paper
• Discovering functional modules by topic modeling RNA-Seq based toxicogenomic data.

  2014cites this paper
• Minireview: Challenges and opportunities in development of PPAR agonists.

  2014cites this paper
• Effect of peroxisome proliferator-activated receptor gamma agonist on heart of rabbits with acute myocardial ischemia/reperfusion injury.

  2014cites this paper
• Conditional Deletion of Cardiomyocyte Peroxisome Proliferator-Activated Receptor &ggr; Enhances Myocardial Ischemia-Reperfusion Injury in Mice

  2014cites this paper
• Essential Role of Protein-tyrosine Phosphatase 1B in the Modulation of Insulin Signaling by Acetaminophen in Hepatocytes*

  2014cites this paper
• Rosiglitazone Dampens Pulmonary Inflammation in a Porcine Model of Acute Lung Injury

  2014cites this paper
• Peroxisome proliferator-activated receptor γ1 and γ2 isoforms alter lipogenic gene networks in goat mammary epithelial cells to different extents.

  2014cites this paper
• Protective effects of pioglitazone against immunoglobulin deposition on heart of streptozotocin-induced diabetic rats

  2014cites this paper
• Developmental and extracellular matrix-remodeling processes in rosiglitazone-exposed neonatal rat cardiomyocytes.

  2014cites this paper
• Explicit role of peroxisome proliferator-activated receptor gamma in gallic acid-mediated protection against ischemia-reperfusion-induced acute kidney injury in rats.

  2014cites this paper
• Cross Talk between Oxidative Stress, PPAR- γ and RAS System in Diabetic Rat Heart Exposed to Ischemia / Reperfusion Injury

  2014cites this paper
• Effect of rosiglitazone on rabbit model of myocardial ischemia-reperfusion injury.

  2013cites this paper
• Effect of Rosiglitazone on Liver Structure and Function in Genetically Diabetic Akita Mice

  2013cites this paper
• A ropinirol és a rosiglitazon proarrhythmiás hatásának vizsgálata kutya kamrai szívizomsejteken

  2013cites this paper
• In Vivo JNK Activation in Pancreatic β-Cells Leads to Glucose Intolerance Caused by Insulin Resistance in Pancreas

  2013cites this paper
• Peroxisome-proliferator-activated receptors regulate redox signaling in the cardiovascular system.

  2013cites this paper
• Diabetes as a negative risk factor for abdominal aortic aneurysm - does the disease aetiology or the treatment provide the mechanism of protection?

  2013cites this paper
• Mechanisms responsible for beneficial and adverse effects of rosiglitazone in a rat model of acute cardiac ischaemia–reperfusion

  2013cites this paper
• Pleiotropic effects of PPARγ agonist on hemostatic activation in type 2 diabetes mellitus.

  2013cites this paper
• Diabetes, perioperative ischaemia and volatile anaesthetics: consequences of derangements in myocardial substrate metabolism

  2013cites this paper
• Prevention of JNK Phosphorylation as a Mechanism for Rosiglitazone in Neuroprotection after Transient Cerebral Ischemia: Activation of Dual Specificity Phosphatase

  2013cites this paper
• Does rosiglitazone affect adiposity and cardiac function in genetic diabetic mice?

  2013cites this paper
• Effect of Taurine on The Respiratory System of Rats

  2013cites this paper
• Rosiglitazone selectively inhibits KATP channels by acting on the KIR6 subunit

  2012cites this paper
• Biology and therapeutic applications of peroxisome proliferator- activated receptors.

  2012cites this paper
• PPAR-γ as a therapeutic target in cardiovascular disease: evidence and uncertainty

  2012cites this paper
• Rosiglitazone protection against experimentally-induced intestinal ischemia/re-perfusion

  2012cites this paper
• Rosiglitazone

  2012cites this paper
• Cardiac dysfunction in adipose triglyceride lipase deficiency: treatment with a PPARα agonist

  2012cites this paper
• Thematic Review Series: New Lipid and Lipoprotein Targets for the Treatment of Cardiometabolic Diseases PPAR- as a therapeutic target in cardiovascular disease: evidence and uncertainty

  2012cites this paper
• Rosiglitazone

  2012cites this paper
• Rosiglitazone negatively regulates c-Jun N-terminal kinase and toll-like receptor 4 proinflammatory signalling during initiation of experimental aortic aneurysms.

  2012cites this paper
• Pioglitazone Attenuates Acute Cocaine Toxicity in Rat Isolated Heart: Potential Protection by Metabolic Modulation

  2011cites this paper
• PPARs and Myocardial Response to Ischemia in Normal and Diseased Heart

  2011cites this paper
• Acute rosiglitazone treatment is cardioprotective against ischemia-reperfusion injury by modulating AMPK, Akt, and JNK signaling in nondiabetic mice.

  2011cites this paper
• PPAR-γ and AMPK--advantageous targets for myocardial ischemia/reperfusion therapy.

  2011cites this paper
• Management of cardiac fibrosis in diabetic rats; the role of peroxisome proliferator activated receptor gamma (PPAR-gamma) and calcium channel blockers (CCBs)

  2011cites this paper
• Effect of rosiglitazone on cardiac electrophysiology, infarct size and mitochondrial function in ischaemia and reperfusion of swine and rat heart

  2011cites this paper
• PPARγ activator, rosiglitazone: Is it beneficial or harmful to the cardiovascular system?

  2011cites this paper
• Can the electrophysiological action of rosiglitazone explain its cardiac side effects?

  2011cites this paper
• Effects of rosiglitazone on the configuration of action potentials and ion currents in canine ventricular cells

  2011cites this paper
• The potential effects of anti-diabetic medications on myocardial ischemia–reperfusion injury

  2011cites this paper
• The role of PPAR in myocardial response to ischemia in normal and diseased heart.

  2011cites this paper
• Untersuchungen zum Einfluss des PPARgamma-Agonisten Rosiglitazon auf die Apoptose isolierter neonataler Kardiomyozyten bei Hypoxie/Reoxygenierung

  2011cites this paper
• AMPK, Akt, and JNK signaling in nondiabetic mice against ischemia-reperfusion injury by modulating Acute rosiglitazone treatment is cardioprotective

  2011cites this paper
• CARDIOPROTECTIVE EFFECTS OF ACUTE ROSIGLITAZONE TREATMENT

  2011cites this paper
• Regulación de la autofagia del cardiomiocito por ligandos farmacológicos del receptor activado por proliferadores peroxisomales gama (PPARγ)

  2011cites this paper
• Rosiglitazone inhibits vascular KATP channels and coronary vasodilation produced by isoprenaline

  2011cites this paper
• Rosiglitazone‐induced myocardial protection against ischaemia–reperfusion injury is mediated via a phosphatidylinositol 3‐kinase/Akt‐dependent pathway

  2010cites this paper
• A native steroid hormone derivative triggers the resolution of inflammation

  2010cites this paper
• Therapeutic Implications of PPARγ in Cardiovascular Diseases

  2010cites this paper
• Telmisartan, an angiotensin-II receptor blocker ameliorates cardiac remodeling in rats with dilated cardiomyopathy

  2010cites this paper
• Pharmacogenomic, Physiological, and Biochemical Investigations on Safety and Efficacy Biomarkers Associated with the Peroxisome Proliferator-Activated Receptor-γ Activator Rosiglitazone in Rodents: A Translational Medicine Investigation

  2010cites this paper
• PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS

  2010cites this paper
• Rosiglitazone reduces tau phosphorylation via JNK inhibition in the hippocampus of rats with type 2 diabetes and tau transfected SH-SY5Y cells.

  2010cites this paper
• Interleukin-4 mediates the neuroprotective effects of rosiglitazone in the aged brain.

  2009cites this paper
• HO-1 activation can attenuate cardiomyocytic apoptosis via inhibition of NF-kappaB and AP-1 translocation following cardiac global ischemia and reperfusion.

  2009cites this paper
• Efficacy and safety of pioglitazone in patients with ST elevation myocardial infarction treated with primary stent implantation

  2009cites this paper
• Delayed presentation of radial artery pseudoaneurysm secondary to catheter trauma during percutaneous coronary intervention

  2009cites this paper
• Rosiglitazone Reduces the Development and Rupture of Experimental Aortic Aneurysms

  2009cites this paper
• EFFECT OF THIAZOLIDINEDIONES ON THE SERUM BIOMARKER LEVELS IN THE NICOTINAMIDE-STREPTOZOTOCIN INDUCED TYPE-2 DIABETES

  2009cites this paper
• Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and disease.

  2009cites this paper
• The PPAR‐γ agonist rosiglitazone facilitates Akt rephosphorylation and inhibits apoptosis in cardiomyocytes during hypoxia/reoxygenation

  2009cites this paper
• Antioxidant therapy in human endocrine disorders.

  2009cites this paper
• Diet-induced obesity influences oocyte developmental competence via peroxisome proliferator-activated receptor gamma (PPARG)-mediated mechanisms.

  2009cites this paper
• PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-&ggr; LIGANDS 15-DEOXY-&dgr;12,14-PROSTAGLANDIN J2 AND PIOGLITAZONE INHIBIT HYDROXYL PEROXIDE-INDUCED TNF-&agr; AND LIPOPOLYSACCHARIDE-INDUCED CXC CHEMOKINE EXPRESSION IN NEONATAL RAT CARDIAC MYOCYTES

  2009cites this paper
• Peroxisome proliferator-activated receptor gamma and cardiovascular diseases.

  2009cites this paper
• Stress hyperglycemia and enhanced sensitivity to myocardial infarction

  2008cites this paper
• Agonists at PPAR‐γ suppress angiotensin II‐induced production of plasminogen activator inhibitor‐1 and extracellular matrix in rat cardiac fibroblasts

  2008cites this paper
• Free radicals and antioxidants in inflammatory processes and ischemia-reperfusion injury.

  2008cites this paper